Chemometric Descriptor Based QSAR Rationales for the MMP-13 Inhibition Activity of Non-Zinc-Chelating Compounds

作者: Brij Kishore Sharma

DOI: 10.4172/2161-0444.1000134

关键词: Applicability domainData miningMatrix (chemical analysis)Linear regressionvan der Waals forceChelationBiological systemEigenvalues and eigenvectorsWeighted distanceQuantitative structure–activity relationshipChemistry

摘要: The MMP-13 inhibition activity of non-zinc-chelating compounds has been quantitatively analyzed in terms chemometric descriptors. statistically validated quantitative structure-activity relationship (QSAR) models provided rationales to explain the these compounds. descriptors, identified through combinatorial protocol multiple linear regression (CP-MLR) analysis, have highlighted role 3-path Kier alpha-modified shape index (S3K), complementary information content 1-order neighborhood symmetry (CIC1), eigenvalue sum from mass weighted distance matrix (SEigm), lowest n. 6 Burden / by atomic van der Waals volumes (BELv6) and polarizabilities (BELp6), 3-order topological charge (GGI3) functionality, R--CR--R (C-025). From models, it appeared that descriptors S3K, BELv6, BELp6 SEigm make positive contribution their higher values are conducive improving MMP- 13 a compound. On other hand, CIC1, GGI3 C-025 render detrimental effects activity. Therefore, absence lower CIC1 would be advantageous. PLS analysis further corroborated dominance CP-MLR Applicability domain revealed suggested acceptable predictability. All within applicability proposed were evaluated correctly.

参考文章(37)
Griffioen Aw, AG-3340 (Agouron Pharmaceuticals Inc). IDrugs : the investigational drugs journal. ,vol. 3, pp. 336- ,(2000)
Hideaki Nagase, J. F. Woessner, Matrix metalloproteinases and TIMPs ,(2000)
Manfred Schudok, Hans Matter, Recent advances in the design of matrix metalloprotease inhibitors. Current Opinion in Drug Discovery & Development. ,vol. 7, pp. 513- ,(2004)
S Wojtowicz-Praga, J Torri, M Johnson, V Steen, J Marshall, E Ness, R Dickson, M Sale, H S Rasmussen, T A Chiodo, M J Hawkins, Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Journal of Clinical Oncology. ,vol. 16, pp. 2150- 2156 ,(1998) , 10.1200/JCO.1998.16.6.2150
B.K. Sharma, P. Singh, K. Sarbhai, Y.S. Prabhakar, A quantitative structure-activity relationship study on serotonin 5-HT6 receptor ligands: indolyl and piperidinyl sulphonamides Sar and Qsar in Environmental Research. ,vol. 21, pp. 369- 388 ,(2010) , 10.1080/10629361003773997
Julie Huxley-Jones, Steven M. Foord, Michael R. Barnes, Drug discovery in the extracellular matrix. Drug Discovery Today. ,vol. 13, pp. 685- 694 ,(2008) , 10.1016/J.DRUDIS.2008.05.005
Susheela Sharma, Yenamandra S. Prabhakar, Prithvi Singh, Brij Kishore Sharma, QSAR study about ATP-sensitive potassium channel activation of cromakalim analogues using CP-MLR approach. European Journal of Medicinal Chemistry. ,vol. 43, pp. 2354- 2360 ,(2008) , 10.1016/J.EJMECH.2008.01.020
B.K. Sharma, P. Singh, M. Shekhawat, K. Sarbhai, Y.S. Prabhakar, Modelling of serotonin reuptake inhibitory and histamine H3 antagonistic activity of piperazine and diazepane amides: QSAR rationales for co-optimization of the activity profiles Sar and Qsar in Environmental Research. ,vol. 22, pp. 365- 383 ,(2011) , 10.1080/1062936X.2011.569895
Tim E. Cawston, Amy J. Wilson, Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Practice & Research: Clinical Rheumatology. ,vol. 20, pp. 983- 1002 ,(2006) , 10.1016/J.BERH.2006.06.007